Pri-Med, a brand owned and operated by M|C Communications LLC, the leading provider of professional education solutions to a community of more than 236,000 clinicians, and ReachMD, the voice of medical professionals on XM radio 160; online for streaming and podcast at www.reachmd.com; and, on the Apple iPhone, today announced the expansion of their strategic collaboration to include two new, original initiatives. The collaboration offers clinicians’ unparalleled access to key medical opinion leaders and is designed to provide world class education that facilitates better practice choices and positively impacts patient care.

Austrian BIOCRATES Life Sciences AG, a prime developer of metabolite biomarkers, and Swiss Selexis SA, a leading biotech company designing high-performance and stable mammalian cell lines for the production of protein drugs, have entered into a co-development agreement with a view to further increasing the drug substance yields from mammalian cell cultures for the pharmaceutical industry. Under the agreement, both parties will combine their knowledge to help lower overall manufacturing costs for pharmacologically active proteins.

Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced today it has entered into an Amended and Restated License, Development and Marketing Agreement with Allergan, Inc., which revises terms related to the PROLACRIA™ (diquafosol tetrasodium ophthalmic solution) 2% development program and Inspire's right to receive revenues from Allergan based on net sales of RESTASIS^® (cyclosporine ophthalmic emulsion) 0.05% and any other human ophthalmic formulations of cyclosporine owned or controlled by Allergan.

DSM Biomedical, a global leader in biomedical materials science, and its Berkeley based operation, DSM PTG, today announced the company has entered into six multi-year licensing agreements with global medical device manufacturers in the Orthopedic, Cardiovascular, Vascular and Urology fields in this year alone. Continuing the company’s successful track record, having also signed nine new license agreements in 2009, DSM Biomedical has a history of partnering with medical device companies to develop new and innovative products that incorporate novel materials and technologies.

Pfenex Inc. and Cedarlane today announced that they have entered into a non-exclusive distribution agreement. Cedarlane will market and distribute high value reagent proteins produced by Pfenex to researchers in Canada and the United States. Among the products initially distributed will be vaccine carrier proteins such as CRM197 and Cholera Toxin B and cell culture related growth factors including G-CSF and Interferon beta 1-b. New products which are developed by Pfenex will be added to the Cedarlane catalogue upon launch.

A new study reveals that the oil and gas industry supply chain – which includes oil companies, contractors and sub-contractors – does not perceive the full extent of the risks that HIV/AIDS, tuberculosis (TB) and malaria pose to its workforce, productivity and profitability. The study – conducted by management consulting firm Booz & Company in partnership the Global Business Coalition on HIV/AIDS, Tuberculosis and Malaria (GBC) – outlines why the oil and gas industry should improve its understanding of the hazards posed by these three epidemics and makes ten recommendations for how to make health a priority.

Positron Corporation (OTCBB:POSC), announced it has signed an agreement with Covidien (NYSE:COV), a leading global provider of healthcare products, under which Covidien will provide technical assistance to Positron in connection with Positron’s development of technology to automate the compounding of radiopharmaceuticals.